Nasdaq · CIK 0001703057
ABCL AbCellera Biologics Inc.
Insider trading from SEC Form 4. Last filing Dec 19, 2025. Close $12.55 on Oct 9, 2026, +351% from the 52-week low and -15% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
ABCLOct 9, 2026 · close 12.55
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AbCellera Biologics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | John S. Montalbano director buy | $178k 50,000 shares | +29% | +89% from low-41% from high | |
| 31Weak | Thermopylae Holdings Ltd. owner buy | $742k 343,631 shares | +1% | - | |
| 38Weak | John S. Montalbano director buy | $58k 25,000 shares | +17% | - | |
| 44Moderate | John S. Montalbano director buy | $141k 60,000 shares | +70% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | Thermopylae Holdings Ltd. owner | GGift Common Shares | -225,000 | $0.00 | $0 | 55,918,640 | Dec 19, 2025 |
| Dec 1, 2025 | Stephen Quake director | AGrant or award Share option (right to buy)derivative | +194,932 | $0.00 | $0 | 194,932 | Dec 19, 2025 |
| Nov 26, 2025 | John S. Montalbano director | POpen-market purchase Common Shares | +50,000 | $3.57 | $178k | 221,000 | Nov 26, 2025 |
| Jun 12, 2025 | Michael R Hayden director | AGrant or award Share option (right to buy)derivative | +238,864 | $0.00 | $0 | 899,843 | Jul 1, 2025 |
| Jun 12, 2025 | Andrew Lo director | AGrant or award Share option (right to buy)derivative | +238,864 | $0.00 | $0 | 541,354 | Jun 16, 2025 |
| Jun 12, 2025 | John S. Montalbano director | AGrant or award Share option (right to buy)derivative | +238,864 | $0.00 | $0 | 1,029,843 | Jun 16, 2025 |
| Mar 11, 2025 | Thermopylae Holdings Ltd. owner | POpen-market purchase Common Shares | +343,631 | $2.16 | $742k | 56,143,640 | Mar 11, 2025 |
| Mar 10, 2025 | John S. Montalbano director | POpen-market purchase Common Shares | +25,000 | $2.30 | $58k | 171,000 | Mar 10, 2025 |
| Mar 6, 2025 | John S. Montalbano director | POpen-market purchase Common Shares | +60,000 | $2.34 | $141k | 146,000 | Mar 7, 2025 |
| Jan 1, 2025 | Carl L. G. Hansen Chief Executive Officer | AGrant or award Share option (right to buy)derivative | +2,730,109 | $0.00 | $0 | 10,990,332 | Jan 3, 2025 |
| Jan 1, 2025 | Andrew Booth Chief Financial Officer | AGrant or award Share option (right to buy)derivative | +1,352,054 | $0.00 | $0 | 7,942,951 | Jan 3, 2025 |
| Jan 1, 2025 | Veronique Lecault Chief Operating Officer | AGrant or award Share option (right to buy)derivative | +832,033 | $0.00 | $0 | 4,661,804 | Jan 3, 2025 |
| Jan 1, 2025 | Tryn Stimart Chief Legal Officer | AGrant or award Share option (right to buy)derivative | +832,033 | $0.00 | $0 | 4,106,747 | Jan 3, 2025 |
| Dec 4, 2024 | Thermopylae Holdings Ltd. owner | GGift Common Shares | -286,000 | $0.00 | $0 | 55,800,009 | Dec 5, 2024 |
| Nov 25, 2024 | Carl L. G. Hansen Chief Executive Officer | MOption exercise Common Shares | +56,125 | $2.70 | $152k | 898,000 | Nov 26, 2024 |
| Nov 25, 2024 | Carl L. G. Hansen Chief Executive Officer | MOption exercise Share option (right to buy)derivative | -56,125 | $0.00 | $0 | 8,260,223 | Nov 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Andrew BoothChief Financial Officer
- Carl L. G. HansenChief Executive Officer
- Michael R Haydendirector
- Veronique LecaultChief Operating Officer
- Andrew Lodirector
- John S. Montalbanodirector
- Stephen Quakedirector
- Tryn StimartChief Legal Officer
- Thermopylae Holdings Ltd.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.